Journal
LANCET NEUROLOGY
Volume 14, Issue 11, Pages 1081-1090Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S1474-4422(15)00249-5
Keywords
-
Categories
Funding
- Allergan
- Amgen
- Alder Biopharmaceuticals
- Arteaus Therapeutics
- CoLucid Pharmaceuticals
- Merck and Co
- eNeura
- NuPathe Pharma
- Eli Lilly and Co
- Autonomic Technologies
- Ethicon
- Supernus Pharmaceuticals
- Labrys Biologics
- Boston Scientific
- Tonix Pharmaceuticals
- Novartis
- Alcobra
- Teva Pharmaceuticals
- MAP Pharmaceuticals
- IntraMed
- Sun Pharma
- Sage
- Oxford University Press
- UpToDate
- Healthlogix
- WebMD
- Universal Meeting Management
- Starr Clinical
- Decision Resources
- Synergy
- Electrocore Medical
- CoLucid
- Bristol-Myers Squibb
- Dr Reddy's Laboratories
- Endo Pharmaceuticals
- Vedanta
- Informa
- Migraine Research Fund
- National Headache Foundation
- National Institutes of Health
Ask authors/readers for more resources
Background Calcitonin gene-related peptide (CGRP) is a validated target for the treatment of episodic migraine. Here we assess the safety, tolerability, and efficacy of TEV-48125, a monoclonal anti-CGRP antibody, in the preventive treatment of high-frequency episodic migraine. Methods In this multicentre, randomised, double-blind, placebo-controlled, phase 2b study, we enrolled men and women (aged 18-65 years) from 62 sites in the USA who had migraine headaches 8-14 days per month. Using a randomisation list generated by a central computerised system and an interactive web response system, we randomly assigned patients (1: 1: 1; stratified by sex and use of concomitant preventive drugs) after a 28 day run-in period to three 28 day treatment cycles of subcutaneous 225 mg TEV-48125, 675 mg TEV-48125, or placebo. Investigators, patients, and the funder were blinded to treatment allocation. Patients reported headache information daily using an electronic diary. Primary endpoints were change from baseline in migraine days during the third treatment cycle (weeks 9-12) and safety and tolerability. The secondary endpoint was change relative to baseline in headache-days during weeks 9-12. Efficacy endpoints were analysed for the intention-to-treat population. Safety and tolerability were analysed using descriptive statistics. This trial is registered at ClinicalTrials.gov, number NCT02025556. Findings Between Jan 8, 2014, and Oct 15, 2014, we enrolled 297 participants: 104 were randomly assigned to receive placebo, 95 to receive 225 mg TEV-48125, and 96 to receive 675 mg TEV-48125. The least square mean (LSM) change in number of migraine-days from baseline to weeks 9-12 was -3.46 days (SD 5.40) in the placebo group, -6.27 days (5.38) in the 225 mg dose group, and -6.09 days (5.22) in the 675 mg dose group. The LSM difference in the reduction of migraine-days between the placebo and 225 mg dose groups was -2.81 days (95% CI -4.07 to -1.55; p<0.0001), whereas the difference between the placebo and 675 mg dose group was -2.64 days (-3.90 to -1.38; p<0.0001). LSM differences in the reduction of headache-days were -2.63 days (-3.91 to -1.34; p<0.0001) between the placebo group and 225 mg dose group and -2.58 days (-3.87 to 1.30; p<0.0001) between the placebo group and the 675 mg dose group. Adverse events occurred in 58 (56%) patients in the placebo group, 44 (46%) patients in the 225 mg dose group, and 57 (59%) patients in the 675 mg dose group; moderate or severe adverse events were reported for 29 (27%) patients, 24 (25%) patients, and 26 (27%) patients, respectively. Interpretation TEV-48125, at doses of 225 mg and 675 mg given once every 28 days for 12 weeks, was safe, well tolerated, and effective as a preventive treatment of high-frequency episodic migraine, thus supporting advancement of the clinical development programme to phase 3 clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available